Norwegian diagnostics company Genetic Analysis has received a U.S. patent approved by the USPTO for a diagnostic method linked to the treatment of irritable bowel syndrome (IBS), according to a press release.The patent covers a method intended to assess the likelihood that patients with IBS will respond to treatment with a low-FODMAP diet or fecal microbiota transplantation, FMT. The patent is valid until November 2040 and has priority from October 2016.The market for IBS diagnostics in the U.S. was estimated to be worth USD 3.3 billion last year.